Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
FDA Bans Imports From Teva's Hungary Plant Except Two Drugs in Shortage | RAPS
Surprise US FDA inspections: Cause for alarm? | Mint
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva expects FDA preapproval inspection of troubled Celltrion plant this year | Fierce Pharma
Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder | 2019-10-10 | FDAnews
Teva Recalls U.S.-Made Drugs Following Contamination Fears | 2021-10-04 | SupplyChainBrain
Teva Pharma Receive Warning Letter - Parker Waichman LLP
After Ignoring Letters From US FDA, Teva And Cipla Will Have ANDAs Withdrawn :: Pink Sheet
Teva confirms US FDA warning letter for Hangzhou, China API plant
Teva Stops Production At US Plant After FDA Concerns: Report
Teva Recalls U.S.-Made Drugs Following Contamination Fears - Bloomberg
Filling errors, counterfeit packs gain FDA's attention | Healthcare Packaging
US FDA eases Teva headache with Ajovy approval
Celltrion FDA warning causes headache for Teva's biologics ambition
FDA to share full inspection reports with EU; Difficult week for Teva, J&J, Mylan | Teva, Radio, Difficult
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns - TheStreet
Teva Lists Irvine Facilities; Industrial Redevelopment Likely - Orange County Business Journal
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd. 4/5/17
Former FDA Inspector Speaks Out About Blood Pressure Medication Recall - Drug And Device Watch
Troubled Teva plant in Hungary faces an FDA crackdown - STAT
Teva Recalls One Lot Of IDArubicin Hydrochloride Injection
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
FDA approves Teva movement disorder treatment - Globes
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
